Promomed Group of Companies has registered a new antitumor drug for the treatment of common cancers

Gemcitabine-Promomed, used for the treatment of pancreatic tumors, non-small cell lung cancer, bladder and breast cancer, has received a registration certificate, becoming the ninth drug in the Promomed Group's oncological portfolio.

The action of the drug is aimed at slowing down or stopping the growth of malignant cells. Once in the body, gembicitabine sequentially forms three metabolites^*, each of which facilitates the incorporation of the final product into DNA, which ultimately leads to blocking the growth of the tumor cell. Gemcitabine's favorable safety profile makes it possible to combine the drug with other cytostatics^**, which in some cases significantly improves treatment results.

The formation of a portfolio of drugs aimed at the treatment of oncological diseases and their introduction to the market is an important strategic task for Promomed Group. The company is focused on solving global medical problems, significantly improving quality and saving patients' lives. When introducing drugs, including generics, to the market, Promomed is working to offer patients effective and safe medicines due to their high quality.

Gemcitabine Promomed will be available in the form of a lyophilizate for the preparation of a concentrate for the preparation of an infusion solution with a dosage of 200 to 1,500 mg, which corresponds to standard treatment regimens.

Like most medicines produced by Promomed Group, this drug is included in the list of VED.

*Metabolite – products of metabolism (metabolism) of any compounds.

Cytostatics (cytostatic drugs) are a group of antitumor drugs that disrupt the growth, development and division mechanisms of all body cells, including malignant cells, thereby initiating cell death.